The aging tumor metabolic microenvironment

Despite the higher incidence of cancer with increasing age, few preclinical or clinical studies incorporate age. This, coupled with an aging world population, requires that we improve our understanding of how aging affects cancer development, progression, and treatment. One key area will be how the...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in biotechnology 2023-12, Vol.84, p.102995-102995, Article 102995
Main Authors: Pilley, Steven E, Esparza, Edgar, Mullen, Peter J
Format: Article
Language:English
Subjects:
Aged
Humans
Neoplasms - therapy
Tumor Microenvironment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the higher incidence of cancer with increasing age, few preclinical or clinical studies incorporate age. This, coupled with an aging world population, requires that we improve our understanding of how aging affects cancer development, progression, and treatment. One key area will be how the tumor microenvironment (TME) changes with age. Metabolite levels are an essential component of the TME, and they are affected by the metabolic requirements of the cells present and systemic metabolite availability. These factors are affected by aging, causing different TME metabolic states between young and older adults. In this review, we will summarize what is known about how aging impacts the TME metabolic state, and suggest how we can improve our understanding of it. •There are similarities in metabolic dysregulation between aging and cancer.•Circulating metabolite levels can change with age and can affect cancer progression.•Aged-induced immune and stromal dysregulation can induce a pro-tumorigenic TME.•It is poorly understood how age affects metabolic pathways in different organs.•Preclinical and clinical studies need to incorporate older ages into their designs.
ISSN:0958-1669
1879-0429
DOI:10.1016/j.copbio.2023.102995